Selank + Semax + DSIP: The Complete Neurological Stack
Selank
Anxiolytic heptapeptide — modulates GABA, serotonin, and enkephalin systems to reduce anxiety without sedation
Semax
Nootropic heptapeptide — enhances BDNF expression, dopaminergic signalling, and cognitive function
DSIP (Delta Sleep-Inducing Peptide)
Nonapeptide — promotes delta-wave sleep, modulates cortisol, and supports circadian rhythm normalisation
Neurological health encompasses three interconnected pillars: emotional regulation (anxiety/stress management), cognitive function (memory, focus, processing speed), and restorative sleep (delta-wave sleep, circadian rhythm integrity). Dysfunction in any one pillar cascades into the others — anxiety impairs cognition and disrupts sleep; poor sleep worsens anxiety and cognitive performance; cognitive decline increases stress and frustration.
This stack addresses all three pillars simultaneously through three Russian-developed peptides with distinct but complementary neurological mechanisms: Selank for anxiolytic support, Semax for cognitive enhancement, and DSIP for sleep optimisation. Each targets different neurotransmitter systems and neurological pathways, creating a comprehensive approach to brain health.
Selank and Semax are both synthetic analogues of endogenous peptides, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Both are approved in Russia as medications. DSIP was originally isolated from rabbit brains in the 1970s and has been researched for sleep and stress applications across multiple decades.
**Critical Disclaimer:** Selank and Semax are approved medications in Russia but NOT in the UK, EU, or US. DSIP is a research compound without approval in any jurisdiction. This content is for educational purposes only. Neurological conditions require professional medical assessment and treatment.
Synergistic Mechanism
Triple-Pillar Neurological Synergy
Selank: The Anxiety Shield
Selank is a synthetic analogue of tuftsin (a naturally occurring tetrapeptide) with an added tripeptide sequence for stability:
- **GABAergic Modulation:** Enhances GABA-A receptor sensitivity without benzodiazepine-like sedation or dependence
- **Serotonin Modulation:** Influences serotonin metabolism, increasing the availability of the 5-HT1A pathway associated with anxiolysis
- **Enkephalin Stabilisation:** Inhibits enkephalinase, increasing endogenous enkephalin levels (natural anxiolytic/analgesic peptides)
- **IL-6 Modulation:** Reduces pro-inflammatory cytokines that can cross the blood-brain barrier and drive neuroinflammation
- **Non-Sedating:** Anxiolytic effects without the cognitive impairment or sedation characteristic of benzodiazepines
- **No Dependence:** Does not produce tolerance, dependence, or withdrawal effects in clinical use (Russia)
Semax: The Cognitive Enhancer
Semax is a synthetic analogue of ACTH(4-10) with a C-terminal tripeptide extension:
- **BDNF Upregulation:** Stimulates expression of Brain-Derived Neurotrophic Factor — the primary neurotrophin supporting neuronal survival, growth, and synaptic plasticity
- **Dopaminergic Enhancement:** Modulates dopamine and serotonin turnover in the brain, supporting attention, motivation, and executive function
- **Neuroprotection:** Demonstrated neuroprotective effects against oxidative stress, excitotoxicity, and ischaemic brain injury
- **Cholinergic Support:** May enhance acetylcholine signalling, supporting memory formation and recall
- **NGF Stimulation:** Upregulates Nerve Growth Factor, supporting neuronal maintenance and repair
- **Clinical Applications (Russia):** Approved for cognitive deficits, stroke recovery, and optic nerve disease
DSIP: The Sleep Restorer
Delta Sleep-Inducing Peptide is an endogenous nonapeptide involved in sleep regulation:
- **Delta-Wave Promotion:** Promotes slow-wave (delta) sleep — the most restorative sleep phase, critical for memory consolidation, tissue repair, and growth hormone release
- **Cortisol Modulation:** May normalise HPA axis function, reducing elevated cortisol that disrupts sleep architecture
- **Circadian Rhythm Support:** Research suggests DSIP influences circadian oscillators, potentially improving sleep-wake cycle regularity
- **Stress Resilience:** Preclinical evidence of improved stress tolerance and reduced stress-related sleep disruption
- **LH/FSH Modulation:** Some evidence of hormonal regulatory effects beyond sleep
The Synergistic Architecture
1. **Daytime Performance:** Selank reduces anxiety while Semax enhances cognition — together, they support calm, focused daytime performance without the anxiety-cognition trade-off seen with many anxiolytics
2. **Night-time Recovery:** DSIP promotes restorative delta-wave sleep, during which neurological repair, memory consolidation, and synaptic pruning occur — processes that benefit from the daytime neurotrophin elevation provided by Semax
3. **Feedback Loop Interruption:** Anxiety (Selank) → poor cognition (Semax) → poor sleep (DSIP) → worse anxiety: this stack targets each link in this common negative cascade
4. **Neurotrophic Continuity:** Semax's BDNF upregulation combined with DSIP's growth hormone-promoting sleep creates an anabolic neurological environment supporting neuronal health and plasticity
Research Evidence
Research Evidence
Selank Research
- **Russian Clinical Approval:** Approved as an anxiolytic medication in Russia; prescribed for generalised anxiety disorder and neurasthenia
- **Clinical Studies:** Double-blind studies show anxiolytic effects comparable to medazepam (a benzodiazepine) without sedation, cognitive impairment, or dependence
- **Zozulya et al. (2008):** Demonstrated Selank's effects on anxiety-related behaviour through GABA and serotonin pathway modulation in rodent models
- **Immune Effects:** Research shows immunomodulatory properties including effects on IL-6 and T-helper cell balance
- **Safety Profile:** Well-characterised in Russian clinical use; intranasal administration is standard
Semax Research
- **Russian Clinical Approval:** Approved for cognitive deficits, ischaemic stroke recovery, and optic nerve atrophy in Russia
- **BDNF Studies:** Multiple publications demonstrate Semax upregulates BDNF and NGF expression in the hippocampus and cortex
- **Stroke Research:** Clinical studies show improved neurological outcomes and cognitive recovery post-stroke
- **Neuroprotection:** Demonstrated protection against oxidative stress and excitotoxicity in neuronal cultures
- **Eremin et al. (2004):** Showed Semax influences dopamine and serotonin metabolism in the striatum and hippocampus
- **Safety Profile:** Well-characterised in Russian clinical use; intranasal administration is standard
DSIP Research
- **Discovery:** Originally isolated by Schoenenberger & Monnier (1977) from rabbit cerebral venous blood during electrically induced sleep
- **Sleep Architecture:** Studies show DSIP normalises disturbed sleep patterns rather than simply inducing sleep — important distinction from hypnotic drugs
- **Stress Resilience:** Schneider-Helmert & Schoenenberger (1986) showed DSIP improved sleep quality in chronic insomniacs, particularly those with stress-related sleep disturbance
- **HPA Axis:** Research suggests DSIP modulates cortisol release, potentially normalising stress-elevated cortisol that disrupts sleep
- **Limited Modern Research:** Despite promising early findings, DSIP has received less research attention in recent decades. Evidence base is smaller than Selank or Semax
Combination Rationale
All three peptides target different neurotransmitter systems (GABA/serotonin, BDNF/dopamine, delta-wave/cortisol) with minimal mechanistic overlap, suggesting additive rather than competing effects. The Russian research tradition that developed Selank and Semax has explored peptide combinations, though this specific triple combination is not formally studied.
Theoretical Protocol
Theoretical Protocol
**Critical Note:** This is a theoretical research protocol. This combination is NOT an approved treatment. Selank and Semax are approved only in Russia. DSIP is not approved anywhere. Use outside Russia requires research-grade compounds with associated quality concerns.
Selank
- **Route:** Intranasal spray (standard in Russian clinical use)
- **Research Dose:** 250-500 mcg per nostril, 2-3 times daily
- **Timing:** Morning and early afternoon (anxiolytic coverage during daytime hours)
- **Duration:** 2-4 week cycles (as per Russian clinical protocols)
Semax
- **Route:** Intranasal spray (standard in Russian clinical use)
- **Research Dose:** 200-600 mcg per nostril, 1-2 times daily
- **Timing:** Morning and early afternoon (cognitive enhancement during active hours)
- **Duration:** 10-30 day courses (as per Russian clinical protocols)
DSIP
- **Route:** Subcutaneous injection or intranasal (research protocols vary)
- **Research Dose:** 100-250 mcg before bed
- **Timing:** 30-60 minutes before intended sleep time
- **Duration:** 5-10 day courses, or intermittent use for sleep disturbance
Administration Notes
- Selank and Semax can be administered in the same session (separate nostrils or sequential)
- DSIP is administered separately in the evening, well separated from daytime peptides
- Intranasal administration provides direct CNS delivery via the olfactory pathway, bypassing the blood-brain barrier
- Start each peptide individually before combining to assess individual response and tolerance
Timing & Scheduling
Selank and Semax are both administered intranasally during the morning and early afternoon to provide anxiolytic and cognitive support during waking hours. They should not be taken in the evening as their activating effects may interfere with sleep onset. DSIP is administered 30-60 minutes before bed to promote delta-wave sleep. This temporal separation — daytime Selank/Semax, evening DSIP — creates a natural cycle of calm focus during the day and restorative sleep at night, avoiding pharmacological conflicts between the wake-promoting and sleep-promoting components.
Expected Outcomes
Expected Outcomes
Individual Component Effects (Based on Available Research):
- Selank: Reduced anxiety without sedation or cognitive impairment, improved emotional stability (Russian clinical data)
- Semax: Enhanced focus, memory, and cognitive processing speed, neuroprotective effects (Russian clinical data)
- DSIP: Improved sleep quality and delta-wave sleep duration, reduced time to sleep onset, normalised sleep architecture
Proposed Combined Outcomes (Theoretical):
- Comprehensive neurological optimisation covering anxiety, cognition, and sleep
- Interruption of the anxiety-cognition-sleep negative feedback loop
- Enhanced daytime performance (calm focus) combined with enhanced night-time recovery
- Sustained neurotrophic support (BDNF from Semax + GH from DSIP-enhanced sleep)
Timeline:
- Days 1-3: Anxiolytic effects of Selank may be noticeable; DSIP sleep effects typically apparent within first few nights
- Days 3-7: Semax cognitive effects begin developing; cumulative anxiolytic benefit
- Weeks 1-2: Full stack effects developing; improved subjective wellbeing and performance
- Weeks 2-4: Established neurological benefits; BDNF-mediated neuroplasticity effects accumulating
Safety Considerations
Safety Considerations
**Selank:** Well-characterised safety profile from Russian clinical use. No significant adverse effects reported at therapeutic doses. No sedation, dependence, or withdrawal. May occasionally cause mild nasal irritation with intranasal administration. Not a controlled substance.
**Semax:** Well-characterised safety profile from Russian clinical use. No significant adverse effects at therapeutic doses. May occasionally cause mild nasal irritation. Theoretical concern about dopaminergic stimulation in individuals with psychotic disorders — should be avoided in schizophrenia or bipolar disorder. Not a controlled substance.
**DSIP:** Limited safety data compared to Selank and Semax. Generally well-tolerated in published research. Some reports of mild morning grogginess. Long-term safety not characterised. Potential hormonal effects (LH/FSH modulation) with prolonged use — short courses are advisable.
Combined Considerations:
- No interaction studies exist for this triple combination
- All three peptides affect central nervous system function — combined CNS effects are unpredictable
- Individuals on psychiatric medications (SSRIs, benzodiazepines, antipsychotics, sleep aids) should NOT combine these peptides with their medications due to unknown interactions
- Start each peptide individually before combining to identify individual response and tolerance
- Discontinue all components if unexpected neurological or psychiatric symptoms occur
- Not suitable for individuals with epilepsy, psychotic disorders, or severe psychiatric conditions
**Quality Concerns:** Outside Russia, Selank and Semax are only available as research-grade compounds. Quality, purity, and accurate dosing cannot be guaranteed from unregulated sources. This is a significant practical safety concern.
**Contraindications:** Active psychiatric disorders (psychosis, bipolar disorder, severe depression). Epilepsy or seizure history. Concurrent psychiatric medication use. Pregnancy or breastfeeding. Under 18 years of age.
Frequently Asked Questions
Conclusion
The Selank + Semax + DSIP stack represents the most comprehensive peptide approach to neurological support, addressing anxiety (Selank), cognition (Semax), and sleep (DSIP) through distinct and complementary mechanisms. Each component targets different neurotransmitter systems — GABA/serotonin, BDNF/dopamine, and delta-wave/cortisol — creating a theoretically non-competing, synergistic framework.
Selank and Semax benefit from Russian clinical approval and decades of clinical use, providing more confidence in their efficacy and safety profiles than most research peptides. DSIP has a smaller evidence base but addresses the critical sleep component that underpins both emotional regulation and cognitive performance.
However, this triple combination has not been formally studied, and combining three CNS-active compounds carries inherent risks. Outside Russia, quality assurance for these peptides is a significant concern. Evidence-based approaches to anxiety (CBT, counselling), cognitive health (exercise, sleep, nutrition), and sleep (sleep hygiene, CBT-I) should always be prioritised.
This content is for educational and informational purposes only. Neurological and psychiatric conditions require professional medical assessment. Never discontinue prescribed medications in favour of research compounds. Selank and Semax are only approved medications in Russia. Consult qualified healthcare professionals in your jurisdiction.